Cambridge Cognition Holdings PLC Cambridge Cognition expands eCOA and wins contract (4407U)
November 25 2019 - 2:00AM
UK Regulatory
TIDMCOG
RNS Number : 4407U
Cambridge Cognition Holdings PLC
25 November 2019
Cambridge Cognition Holdings Plc
("Cambridge Cognition" or the "Company")
Cambridge Cognition expands eCOA offering and wins
$225,000 contract with top 10 pharmaceutical company
Cambridge Cognition Holdings plc (AIM: COG), which develops and
markets digital solutions to assess brain health, is pleased to
announce the launch of an improved electronic clinical outcomes
assessment ("eCOA") platform that has already attracted a new
client from one of the world's top 10 pharmaceutical companies.
Clinicians and patients complete clinical outcome assessments
(COAs), such as questionnaires and scales, during clinical trials
in order to monitor the effects of treatment. With the ubiquity of
electronic devices, these necessary assessments are increasingly
being delivered on smartphones, tablets and desktops, and so much
so that the eCOA market is estimated to reach $2 billion by 2025(1)
.
After investing proceeds from the fundraise earlier this year,
Cambridge Cognition has expanded its eCOA offering to include
complex forms, alerting, interview recording and playback.
Following the launch of the enhanced functionality the Company is
pleased to announce a new clinical trial contract worth over
US$225,000.
The Company's eCOA solution can be rapidly configured for each
new clinical trial. This means that deployment of new clinical
outcome instruments takes days, rather than weeks or months, once
the licences have been secured.
This new contract has tight study deadlines, with multiple
outcome assessments for over 100 patients across five time-points.
In using the Company's automated assessment system, the
administrative burden for sites is reduced, while consistency in
data collection and quality is ensured. Crucially, having a single
platform to deliver both electronic questionnaires and scales,
alongside the Company's CANTAB(TM) cognitive assessments, provides
a seamless user experience for the patient.
Commenting, Matthew Stork, Chief Executive Officer of Cambridge
Cognition, said:
"Increasingly, pharmaceutical and biotech companies are
recognising the operational benefits of delivering questionnaires
and scales electronically in their clinical trials. Our new eCOA
offering enables us to capitalise on this shift and to provide an
extremely fast turn-around from contract agreement to study
deployment. We are pleased to see that the investment in
development made this year has already helped us to build a new
relationship with another prestigious partner. We look forward to
this being one of many such partnerships."
The information communicated in this announcement contains
inside information for the purposes of Article 7 of the Market
Abuse Regulation (EU) No. 596/2014.
For further information, contact:
Cambridge Cognition Holdings PLC Tel: 012 2381 0700
Matthew Stork, Chief Executive Officer press@camcog.com
Nick Walters, Chief Financial Officer
finnCap Ltd (NOMAD and Joint Broker) Tel: 020 7220 0500
Geoff Nash / Simon Hicks (Corporate Finance)
Alice Lane / Manasa Patil (Corporate Broking)
Dowgate Capital Limited (Joint Broker) Tel: 020 3903 7715
David Poutney / James Serjeant
IFC Advisory Ltd (Financial PR and IR) Tel: 020 3934 6630
Tim Metcalfe / Graham Herring / Zach Cohen
Notes to Editors
References
1. Electronic Clinical Outcome Assessment Market : Grand View Research
About Cambridge Cognition
Cambridge Cognition is a neuroscience technology company
developing digital health products to better understand, detect and
treat conditions affecting brain health. The company's software
products assess cognitive health in patients worldwide to improve
clinical trial outcomes, identify and stratify patients early and
improve global efficiency in pharmaceutical and healthcare
industries.
For further information visit www.cambridgecognition.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCEANFAAAANFFF
(END) Dow Jones Newswires
November 25, 2019 02:00 ET (07:00 GMT)
Cambridge Cognition (LSE:COG)
Historical Stock Chart
From Apr 2024 to May 2024
Cambridge Cognition (LSE:COG)
Historical Stock Chart
From May 2023 to May 2024